Key takeaways from Cipla’s first biosimilar launch

On April 17, Cipla launched its first biosimilar drug in India. The product is Etacept, a branded biosimilar of Pfizer's Enbrel (etanercept). The drug treats rheumatoid arthritis (RA) an autoimmune disease that leads to painful and debilitating inflammation, predominantly of the joints, and is estimated to impact 0.7 per cent of the Indian population above …

Advertisement

What does Glivec ruling imply for generics? My piece in Sunday ET

In case some of you were waiting for Apothecury's take on the Glivec judgement, I was waiting for this piece that I did for the Sunday Economic Times to be published. In a nutshell, in the article I explain why, as far as India's generics industry is concerned, the Glivec outcome is not really a …